Document is current

Article History

Received: 25 September 2024

Accepted: 11 December 2024

First Online: 20 February 2025

Declarations

:

: Bernhard J. Steinhoff has received honoraria for consulting from Angelini Pharma, B. Braun Melsungen, Desitin, Eisai, and UCB, for serving on a scientific advisory board from GW Pharmaceuticals, Precisis, UCB, and Zogenix, and for speaking from Arvelle, Desitin, Eisai, Hikma Pharmaceuticals, UCB, and Zogenix, and has received research support from Eisai, SK Life Science, and UCB. Jakob Christensen has received honoraria from serving on the scientific advisory board of Eisai AB and UCB, received honoraria for giving lectures from Eisai AB and UCB, and received funding for a trip from UCB. Colin P. Doherty has received honoraria from Eisai and UCB. Marian Majoie has received financial compensation through her institution for participating in contract research from Eisai, GW Pharmaceuticals, UCB, and Zogenix. Anne-Liv Schulz, Fiona Brock, Dimitrios Bourikas, and Iryna Leunikava are employees of UCB. Anne-Liv Schulz and Dimitrios Bourikas have received UCB stocks from their employment. Anna Kelemen has received honoraria for serving on advisory boards from Eisai and Zogenix, and has received honoraria for lectures and publications from GW Pharmaceuticals, Richter Gedeon, and UCB. Eduardo Rubio-Nazabal has received honoraria from BIAL, Eisai, and UCB for speaking.

: The study protocol was reviewed and approved by an Institutional Review Board/Independent Ethics Committee (see Institutional Review Board/Independent Ethics Committee appendix in the Supplementary Material), according to country-specific regulations. Written data consent was obtained from the patient, parent(s), or legal representative before study participation, in accordance with local regulations and the Declaration of Helsinki.